Tangui Le Guen1, Fabien Touzot2, Isabelle André-Schmutz3, Chantal Lagresle-Peyrou4, Benoit France1, Laetitia Kermasson1, Nathalie Lambert5, Capucine Picard6, Patrick Nitschke7, Wassila Carpentier8, Christine Bole-Feysot9, Annick Lim10, Marina Cavazzana11, Isabelle Callebaut12, Jean Soulier13, Nada Jabado14, Alain Fischer3, Jean-Pierre de Villartay1, Patrick Revy15. 1. INSERM UMR 1163, Laboratory of Genome Dynamics in the Immune System, Paris, France; Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Paris, France. 2. INSERM UMR 1163, Laboratory of Genome Dynamics in the Immune System, Paris, France; Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Paris, France; AP-HP, Hôpital Necker Enfants-Malades, Service d'Immunologie et d'Hématologie Pédiatrique, Paris, France. 3. Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Paris, France; AP-HP, Hôpital Necker Enfants-Malades, Service d'Immunologie et d'Hématologie Pédiatrique, Paris, France. 4. Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Paris, France; CIC-BT 502 INSERM, Paris, France, and Département de Biothérapie, AP-HP, Hôpital Necker-Enfants Malades, Paris, France. 5. AP-HP, Hôpital Necker Enfants-Malades, Service d'Immunologie et d'Hématologie Pédiatrique, Paris, France; Study Center of Primary Immunodeficiencies, AP-HP, Necker Hospital, Paris, France. 6. Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Paris, France; AP-HP, Hôpital Necker Enfants-Malades, Service d'Immunologie et d'Hématologie Pédiatrique, Paris, France; Study Center of Primary Immunodeficiencies, AP-HP, Necker Hospital, Paris, France. 7. Service de Bioinformatique, Faculté de Médecine Pitié Salpêtrière, Paris, France. 8. Plateforme Post-Génomique P3S, Faculté de Médecine Pitié Salpêtrière, Paris, France. 9. Plateforme de génomique, Institut Imagine, Paris, France. 10. Institut Pasteur, Groupe Immunoscope, Département d'Immunologie, Paris, France. 11. Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Paris, France; Study Center of Primary Immunodeficiencies, AP-HP, Necker Hospital, Paris, France. 12. CNRS UMR7590, Sorbonne Universités, Université Pierre et Marie Curie-Paris6-MNHN-IRD-IUC, Paris, France. 13. INSERM U944, Institut universitaire d'Hématologie, Université Denis Diderot, Paris, France. 14. McGill University and the Genome Quebec Innovation Centre, Montreal, Quebec, Canada. 15. INSERM UMR 1163, Laboratory of Genome Dynamics in the Immune System, Paris, France; Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Paris, France. Electronic address: patrick.revy@inserm.fr.
Abstract
BACKGROUND: Myb-Like, SWIRM, and MPN domains 1 (MYSM1) is a metalloprotease that deubiquitinates the K119-monoubiquitinated form of histone 2A (H2A), a chromatin marker associated with gene transcription silencing. Likewise, it has been reported that murine Mysm1 participates in transcription derepression of genes, among which are transcription factors involved in hematopoietic stem cell homeostasis, hematopoiesis, and lymphocyte differentiation. However, whether MYSM1 has a similar function in human subjects remains unclear. Here we describe a patient presenting with a complete lack of B lymphocytes, T-cell lymphopenia, defective hematopoiesis, and developmental abnormalities. OBJECTIVES: We sought to characterize the underlying genetic cause of this syndrome. METHODS: We performed genome-wide homozygosity mapping, followed by whole-exome sequencing. RESULTS: Genetic analysis revealed that this novel disorder is caused by a homozygous MYSM1 missense mutation affecting the catalytic site within the deubiquitinase JAB1/MPN/Mov34 (JAMM)/MPN domain. Remarkably, during the course of our study, the patient recovered a normal immunohematologic phenotype. Genetic analysis indicated that this improvement originated from a spontaneous genetic reversion of the MYSM1 mutation in a hematopoietic stem cell. CONCLUSIONS: We here define a novel human immunodeficiency and provide evidence that MYSM1 is essential for proper immunohematopoietic development in human subjects. In addition, we describe one of the few examples of spontaneous in vivo genetic cure of a human immunodeficiency.
BACKGROUND:Myb-Like, SWIRM, and MPN domains 1 (MYSM1) is a metalloprotease that deubiquitinates the K119-monoubiquitinated form of histone 2A (H2A), a chromatin marker associated with gene transcription silencing. Likewise, it has been reported that murineMysm1 participates in transcription derepression of genes, among which are transcription factors involved in hematopoietic stem cell homeostasis, hematopoiesis, and lymphocyte differentiation. However, whether MYSM1 has a similar function in human subjects remains unclear. Here we describe a patient presenting with a complete lack of B lymphocytes, T-cell lymphopenia, defective hematopoiesis, and developmental abnormalities. OBJECTIVES: We sought to characterize the underlying genetic cause of this syndrome. METHODS: We performed genome-wide homozygosity mapping, followed by whole-exome sequencing. RESULTS: Genetic analysis revealed that this novel disorder is caused by a homozygous MYSM1 missense mutation affecting the catalytic site within the deubiquitinase JAB1/MPN/Mov34 (JAMM)/MPN domain. Remarkably, during the course of our study, the patient recovered a normal immunohematologic phenotype. Genetic analysis indicated that this improvement originated from a spontaneous genetic reversion of the MYSM1 mutation in a hematopoietic stem cell. CONCLUSIONS: We here define a novel humanimmunodeficiency and provide evidence that MYSM1 is essential for proper immunohematopoietic development in human subjects. In addition, we describe one of the few examples of spontaneous in vivo genetic cure of a humanimmunodeficiency.
Authors: Jacob C Ulirsch; Jeffrey M Verboon; Shideh Kazerounian; Michael H Guo; Daniel Yuan; Leif S Ludwig; Robert E Handsaker; Nour J Abdulhay; Claudia Fiorini; Giulio Genovese; Elaine T Lim; Aaron Cheng; Beryl B Cummings; Katherine R Chao; Alan H Beggs; Casie A Genetti; Colin A Sieff; Peter E Newburger; Edyta Niewiadomska; Michal Matysiak; Adrianna Vlachos; Jeffrey M Lipton; Eva Atsidaftos; Bertil Glader; Anupama Narla; Pierre-Emmanuel Gleizes; Marie-Françoise O'Donohue; Nathalie Montel-Lehry; David J Amor; Steven A McCarroll; Anne H O'Donnell-Luria; Namrata Gupta; Stacey B Gabriel; Daniel G MacArthur; Eric S Lander; Monkol Lek; Lydie Da Costa; David G Nathan; Andrei A Korostelev; Ron Do; Vijay G Sankaran; Hanna T Gazda Journal: Am J Hum Genet Date: 2018-11-29 Impact factor: 11.025
Authors: Bianca Tesi; Josef Davidsson; Matthias Voss; Elisa Rahikkala; Tim D Holmes; Samuel C C Chiang; Jonna Komulainen-Ebrahim; Sorina Gorcenco; Alexandra Rundberg Nilsson; Tim Ripperger; Hannaleena Kokkonen; David Bryder; Thoas Fioretos; Jan-Inge Henter; Merja Möttönen; Riitta Niinimäki; Lars Nilsson; Cornelis Jan Pronk; Andreas Puschmann; Hong Qian; Johanna Uusimaa; Jukka Moilanen; Ulf Tedgård; Jörg Cammenga; Yenan T Bryceson Journal: Blood Date: 2017-02-15 Impact factor: 22.113
Authors: Fernanda Gutierrez-Rodrigues; Sushree S Sahoo; Marcin W Wlodarski; Neal S Young Journal: Best Pract Res Clin Haematol Date: 2021-06-27 Impact factor: 3.670
Authors: Bochao Danae Lin; Elena Carnero-Montoro; Jordana T Bell; Dorret I Boomsma; Eco J de Geus; Rick Jansen; Cornelis Kluft; Massimo Mangino; Brenda Penninx; Tim D Spector; Gonneke Willemsen; Jouke-Jan Hottenga Journal: J Hum Genet Date: 2017-08-03 Impact factor: 3.172